235 related articles for article (PubMed ID: 31905298)
21. Management of Psoriatic Arthritis: Traditional Disease-Modifying Rheumatic Agents and Targeted Small Molecules.
Soriano ER
Rheum Dis Clin North Am; 2015 Nov; 41(4):711-22. PubMed ID: 26476228
[TBL] [Abstract][Full Text] [Related]
22. Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs.
Tucker L; Allen A; Chandler D; Ciurtin C; Dick A; Foulkes A; Gullick N; Helliwell P; Jadon D; Jones G; Kyle S; Madhok V; McHugh N; Parkinson A; Raine T; Siebert S; Smith C; Tillett W; Coates LC
Rheumatology (Oxford); 2022 Aug; 61(9):3514-3520. PubMed ID: 35640653
[No Abstract] [Full Text] [Related]
23. Qualitative assessment of medication adherence in patients with rheumatic diseases on biologic therapy.
Raghunath S; Hijjawi R; Hoon E; Shanahan EM; Goldblatt F
Clin Rheumatol; 2019 Oct; 38(10):2699-2707. PubMed ID: 31172365
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A; Smolen JS; Dougados M; de Wit M; Primdahl J; McInnes I; van der Heijde D; Baraliakos X; Falzon L; Gossec L
Ann Rheum Dis; 2020 Jun; 79(6):778-786. PubMed ID: 32381564
[TBL] [Abstract][Full Text] [Related]
25. Effect of biologics on fatigue in psoriatic arthritis: A systematic literature review with meta-analysis.
Reygaerts T; Mitrovic S; Fautrel B; Gossec L
Joint Bone Spine; 2018 Jul; 85(4):405-410. PubMed ID: 29452303
[TBL] [Abstract][Full Text] [Related]
26. Pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biologic and non-biologic DMARDs.
Soriano ER; Acosta-Felquer ML; Luong P; Caplan L
Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):793-806. PubMed ID: 25488785
[TBL] [Abstract][Full Text] [Related]
27. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
[TBL] [Abstract][Full Text] [Related]
28. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.
Elyoussfi S; Thomas BJ; Ciurtin C
Rheumatol Int; 2016 May; 36(5):603-12. PubMed ID: 26892034
[TBL] [Abstract][Full Text] [Related]
29. Updated guidelines for the management of axial disease in psoriatic arthritis.
Nash P; Lubrano E; Cauli A; Taylor WJ; Olivieri I; Gladman DD
J Rheumatol; 2014 Nov; 41(11):2286-9. PubMed ID: 25362712
[TBL] [Abstract][Full Text] [Related]
30. Switching biologics in the treatment of psoriatic arthritis in Japan.
Yamamoto T; Ohtsuki M; Sano S; Morita A; Igarashi A; Okuyama R; Kawada A;
J Dermatol; 2019 Mar; 46(3):e113-e114. PubMed ID: 30156313
[No Abstract] [Full Text] [Related]
31. Recommendations of the Spanish Society of Rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis.
Torre Alonso JC; Díaz Del Campo Fontecha P; Almodóvar R; Cañete JD; Montilla Morales C; Moreno M; Plasencia-Rodríguez C; Ramírez García J; Queiro R
Reumatol Clin (Engl Ed); 2018; 14(5):254-268. PubMed ID: 29111261
[TBL] [Abstract][Full Text] [Related]
32. The role of methotrexate in psoriatic arthritis: what is the evidence?
Ianculescu I; Weisman MH
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S94-7. PubMed ID: 26470718
[TBL] [Abstract][Full Text] [Related]
33. Biologics and small molecules in the management of psoriatic arthritis: Reproduction related issues in female and male patients.
Fischer-Betz R; Østensen M
Expert Rev Clin Pharmacol; 2021 Aug; 14(8):979-989. PubMed ID: 33982647
[TBL] [Abstract][Full Text] [Related]
34. Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis.
Stiff KM; Glines KR; Porter CL; Cline A; Feldman SR
Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1209-1218. PubMed ID: 30449211
[TBL] [Abstract][Full Text] [Related]
35. The Changing Face of Clinical Trials in Psoriatic Arthritis.
Ogdie A; Coates L
Curr Rheumatol Rep; 2017 Apr; 19(4):21. PubMed ID: 28365920
[TBL] [Abstract][Full Text] [Related]
36. Psoriatic Arthritis: Newer and Older Therapies.
Chao R; Kavanaugh A
Curr Rheumatol Rep; 2019 Dec; 21(12):75. PubMed ID: 31865449
[TBL] [Abstract][Full Text] [Related]
37. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
[TBL] [Abstract][Full Text] [Related]
38. Switching biologics in the treatment of psoriatic arthritis.
Merola JF; Lockshin B; Mody EA
Semin Arthritis Rheum; 2017 Aug; 47(1):29-37. PubMed ID: 28363434
[TBL] [Abstract][Full Text] [Related]
39. Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysis.
Ungprasert P; Thongprayoon C; Davis JM
Semin Arthritis Rheum; 2016 Feb; 45(4):428-38. PubMed ID: 26610638
[TBL] [Abstract][Full Text] [Related]
40. Therapy strategies in psoriatic arthritis.
Coates LC
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S70-2. PubMed ID: 26470949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
